Search Results

December 2021 "Dame Carol Robinson DBE, FRS, FRSC, FMedSci, Oxford University’s first female Professor of Chemistry , former president of the Royal Society of Chemistry and Founder of (and ongoing consultant to) OMass

members — Susanna Naggie, MD, and Sudarshan Rajagopal, MD, PhD — have been elected to the American Society Naggie and Rajagopal are two of 95 new members elected to the society for 2022.

GPCR Podcast, is filled with such moments, from bombing her first high school chemistry test to co-founding She studied pharmacy with a specialization in pharmaceutical chemistry, a degree that allowed her to Maria Majellaro Now, she leads a team of talented chemists at Celtarys, developing fluorescent ligands

The Early Days: Molecules and Mentors Alessandro began his academic life studying pharmaceutical chemistry While fascinated by organic chemistry and the idea of “building molecules,” he didn’t see the big picture—until Suddenly, chemistry wasn’t just synthetic—it was strategic. Falling for Computational Chemistry Alessandro’s master’s thesis brought him face to face with his “second academic love”: computational chemistry .

Our CSO, Maria, has recently traveled to the US to attend the ACSMEDI-EFMC Medicinal Chemistry Frontiers conference organized by both the EFMC and the ACSMEDI, in an effort to share the most novel medicinal chemistry Another section was dedicated to Chemistry Tools, highlighting their importance. This Chemistry Tools session was more industry focused than those before, and Maria shared the floor

Molecular innovation This Week’s GPCR Intelligence: The next edge in discovery isn’t louder exposure—it’s smarter engagement. This week’s Dr. Kenakin from Terry's Corner shows how to tame irreversible drugs so their kinetic power works for you, not against you. You’ll get a framework to predict duration, penetration, and PK/PD separation—so decisions move faster and risks surface earlier. Breakthroughs this week:  nanomedicines targeting PAR2 for sustained analgesia; Emerging Voices in GPCR Biology; Domain Therapeutics patents new PAR2 antagonists. 🔍 This Week in Dr. GPCR Premium: Sneak Peek Industry insights:  Confo VLAIO grant; Skye CB1 Ph2 miss; Chugai CT-388 in-license; Septerna valuation. Upcoming events:  Membrane-mimetic screening; GPCR Forum 2025; GPCR-TDD Summit Europe. Career opportunities:  Sr. Scientist—In-vitro Pharm; Postdoc roles. Must-read publications:  AT1R β-arrestin bias; UII receptor structure; β2AR constant-pH dynamics. Terry's Corner – Control Target Engagement—Don’t Chase It with Irreversible Drugs When binding outlives exposure, everything changes. This feature frames how to define “irreversible” in real systems, anticipate PK/PD separation, and use target turnover to tune duration. You’ll see why tight binding can backfire on tissue penetration, where k_inact/K_I beats classic Ki, and how to quantify what matters—speed of inactivation and durability of effect. If your team is designing covalent or tight-binding candidates, these principles reduce surprises and accelerate dose optimization. You’ll avoid costly missteps by: Preventing kinetic traps —spot PK/PD decoupling early so washouts and C_max don’t mislead dosing strategy. Designing for penetration —balance on/off rates to reach inner tissue, not just peripheries. Quantifying what counts —prioritize k_inact and k_inact/K_I to compare irreversible inhibitors realistically. 🎥  Live AMA with Dr. Kenakin — October 30, 12 PM EST   Join Dr. Kenakin live and bring the questions that keep you thinking. Each AMA feeds directly into next month’s lessons—your real-world challenges shape what comes next.   Your Membership Gives You: Proven frameworks used in real discovery programs On-demand lessons built for tight research schedules A say in the topics covered next Weekly updates that keep your knowledge sharp Monthly live AMAs with Dr. Kenakin Trusted insights from biotech, pharma, and academia 🎬 Plus New: Lesson Trailers   Curious about Terry’s Corner before committing? Watch our new trailers for a preview of expert-led GPCR training designed for scientists and drug hunters.    💎  $2,999/year — the cost of one conference = a year of expert training — Premium Members Enjoy Over 50% Discount at Checkout Get Yearly Access On-Demand Now — Free 7 Day Trial ➤ DrGPCR Podcast: Jens Carlsson on Predictive Modeling Prediction over explanation—that’s the shift. Jens Carlsson shares how structure-based design, molecular dynamics, and smart collaboration turn models into decisions, with practical guardrails on AlphaFold’s limits. Ideal for scientists who want modeling to guide experiments, not just narrate them. Value at a glance: From screens to hits —how to identify novel GPCR ligands with structure-based workflows. Know the limits —where AI helps and where it still overpromises. Bridge the aisle —modelers × experimentalists for faster iteration. Listen to the episode ➤ Why Dr. GPCR Premium Membership Gives You an Edge Premium provides scientists with weekly expert lectures, industry updates, priority events, targeted roles, and editorial context, allowing proactive action before signals become headlines. It’s an operating system for discovery decisions, featuring practical frameworks, trusted curations, and a community that accelerates your progress. Staying current is essential as kinetics, structure, and signaling evolve rapidly. Premium keeps you oriented and out of avoidable dead-ends. FAQ 🔹 What’s included?   The complete Weekly News digest, curated jobs, upcoming events, classified GPCR publications, and on-demand expert frameworks—plus member-only discounts. 🔹 Who is it for?   GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need fast, curated, career-relevant intelligence. 🔹 Why now?   GPCR innovation is accelerating; act on the right signals today to shape tomorrow’s breakthroughs—and avoid delays others won’t see coming 👉 Already a Premium Member? Access this week’s full Premium Edition here ➤ What our members say "Thank you for bringing this course with Dr. Kenakin… sorely needed in the field." — DrGPCR University Attendee 🚀 Join now — and learn to design drugs that don’t just bind tighter, but work smarter and last longer. Become a Premium Member today. ➤ 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage

leadership wasn’t meticulously planned, it was a bold leap fueled by gut instinct and a deep love for chemistry GPCR Podcast, she shares how her background in medicinal chemistry paved the way to co-founding Celtarys Over time, she developed a fascination with how molecules influence biology and how that chemistry could company page . _______________ Keyword Cloud:   GPCR drug discovery , GPCR research community , medicinal chemistry

August 2022 "GPCRs in Medicinal Chemistry Event 8th RSC / SCI symposium on GPCRs in Medicinal Chemistry

October 2022 "Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealised, therapeutic potential. Promising preclinical data supports the applicability of CB2 activation in autoimmune and inflammatory diseases, pain, neurodegeneration, and osteoporosis. A diverse pharmacopoeia of cannabinoid ligands is available, which has led to considerable advancements in the understanding of CB2 function and extensive preclinical evaluation. However, until recently, most CB2 ligands were highly lipophilic and as such not optimal for clinical application due to unfavourable physicochemical properties. A number of strategies have been applied to develop CB2 ligands to achieve closer to 'drug-like' properties and a few such compounds have now undergone clinical trial. We review the current state of CB2 ligand development and progress in optimising physicochemical properties, understanding advanced molecular pharmacology such as functional selectivity, and clinical evaluation of CB2-targeting compounds." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealized, therapeutic potential. Promising preclinical data support the applicability of CB2 activation in autoimmune and inflammatory diseases, pain, neurodegeneration, and osteoporosis. A diverse pharmacopeia of cannabinoid ligands is available, which has led to considerable advancements in the understanding of CB2 function and extensive preclinical evaluation. However, until recently, most CB2 ligands were highly lipophilic and as such, not optimal for clinical application due to unfavorable physicochemical properties. A number of strategies have been applied to develop CB2 ligands to achieve closer to 'drug-like' properties and a few such compounds have now undergone clinical trials. We review the current state of CB2 ligand development and progress in optimizing physicochemical properties, understanding advanced molecular pharmacology such as functional selectivity, and clinical evaluation of CB2-targeting compounds." Read more at the source #DrGPCR #GPCR #IndustryNews

Reviews, GPCRs, and more Recent Studies on Serotonin 5-HT2A Receptor Antagonists in Medicinal Chemistry Proteins Professor Andrew Hopkins, Exscientia’s founder and CEO, was elected as a Fellow of the The Royal Society. Participants Diagnosed with WHIM Syndrome GPCR Events, Meetings, and Webinars ASPET 2023 - American Society

an incredible week filled with prestigious events, including receiving the British Pharmacological Society XXIII GEM Meeting in 2025 April 3 - 6, 2025 | ASPET 2025 April 14 - 17, 2025 | 20th Drug Discovery Chemistry Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic Senior Principal Scientist, Medicinal Chemistry

BIOGRAPHICAL MEMOIRS OF FELLOWS OF THE ROYAL SOCIETY 70, 23–40 (2021). https://royalsocietypublishing.org The Nobel Prize in Chemistry 2012 - NobelPrize.org. https://www.nobelprize.org/prizes/chemistry/2012/ /prizes/chemistry/2012/popular-information/. 66. /prizes/chemistry/2012/advanced-information/. 67. Chemistry, R. S. of.

Japan Septerna files for IPO on strength of preclinical data, vision for expanding GPCR landscape The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2024 Septerna Announces cell function Protein Biochemist/Structural Biologist Senior Scientist/Staff Scientist, Computational Chemistry

Congratulations to our amazing Board Member JoAnn Trejo for being elected to the British Pharmacological Society XXIII GEM Meeting in 2025 April 3 - 6, 2025 | ASPET 2025 April 14 - 17, 2025 | 20th Drug Discovery Chemistry Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic Senior Principal Scientist, Medicinal Chemistry

It was the result of chemistry, collaboration, and relentless effort until the signal finally confirmed The Chemistry That Almost Didn’t Work Designing pH-sensitive rare-earth complexes was not an obvious The chemistry involved is notoriously complex. Solubility poses significant challenges. The chemistry originated from Parker’s lab. What started as a chemistry problem has evolved into a discovery platform.

of Discovery pHSense wasn’t built in a vacuum—it was born from decades of groundwork in rare earth chemistry It’s the product of layered collaborations—with Durham University chemist David Parker on the probe chemistry

GPCR Partner Tools The Story Behind Celtarys – From Chemistry to Company   How does a medicinal chemist

Day Addex Therapeutics attended the Swiss Biotech Day Sosei Heptares presented novel Computational Chemistry GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

Maria Majellaro Celtarys specializes in the custom development of fluorescent ligands  using a modular chemistry But what sets them apart isn’t just chemistry. It’s empathy.

This is Lucía from the Celtarys Research chemistry team.  It’s reversible under non-reducing conditions. [ 4]     Other strategies include click chemistry,  more -dipolar cycloaddition), which is a very robust conjugation strategy to obtain linkers with a rigid moiety Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions In Comprehensive Analytical Chemistry ; Verma, S. K., Das, A.

Endocrinology and Pharmacology, Professor Kevin Pfleger, was appointed President of the Australasian Society Coincidentally, on the same day, Prof Pfleger was announced as a Fellow of the British Pharmacological Society "ASCEPT is the peak professional society devoted to advancing excellence in Clinical and Experimental “I am honoured to be appointed President of ASCEPT, and am particularly excited given the Society’s conference

That’s where computational chemistry steps in. This case study highlights why computational chemistry is no longer a side tool—it’s a driver of discovery

Explore Terry's Corner From Chemistry Lab to GPCR Partner – New Podcast with Celtarys Dr. Maria Majellaro of Celtarys shares how her team translates medicinal chemistry into practical GPCR assay

He went on to study medicine at the Royal College of Surgeons in Ireland before receiving his Medical

Here’s the surprising truth: up to 80% of GPCR-targeted drugs fail—not because of poor chemistry, but

You’ll uncover: Why pharmacology is the glue between chemistry and biology How to interpret drug behavior

It started not with biology—but with chemistry. Revvity and academic collaborator Prof. Mini Timeline: The Road to pHSense → Initial lanthanide probe design with Durham University (chemistry Revnity’s partnership with Durham (chemistry) and the Institute of Functional Genomics in Montpellier

Receptors: A Century of Research and Discovery Challenges and opportunities in cancer immunotherapy: a Society assays in drug discovery October 2024 | Biologics US 2024 October 2 - 4, 2024 | 9th GPCRs in Medicinal Chemistry

GPCR University Learner Celtarys Research Recap: Medicinal Chemistry Highlights You May Have Missed The pace of innovation in medicinal chemistry is accelerating—and if you missed this year’s ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025 , you’re already behind.